vs
ARTIVION, INC.（AORT）与iRhythm Holdings, Inc.（IRTC）财务数据对比。点击上方公司名可切换其他公司
iRhythm Holdings, Inc.的季度营收约是ARTIVION, INC.的1.8倍（$208.9M vs $116.0M）。iRhythm Holdings, Inc.净利率更高（2.7% vs 2.1%，领先0.6%）。iRhythm Holdings, Inc.同比增速更快（27.1% vs 19.2%）。iRhythm Holdings, Inc.自由现金流更多（$14.5M vs $-7.9M）。过去两年iRhythm Holdings, Inc.的营收复合增速更高（25.8% vs 9.1%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
iRhythm Holdings是一家专注于心脏护理领域的数字医疗企业，开发可穿戴动态心脏监测设备及配套AI分析工具，主要服务美国市场的医疗机构与患者，帮助检测房颤等心律异常病症，为临床诊断提供可靠的数据支持。
AORT vs IRTC — 直观对比
营收规模更大
IRTC
是对方的1.8倍
$116.0M
营收增速更快
IRTC
高出7.9%
19.2%
净利率更高
IRTC
高出0.6%
2.1%
自由现金流更多
IRTC
多$22.4M
$-7.9M
两年增速更快
IRTC
近两年复合增速
9.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $208.9M |
| 净利润 | $2.4M | $5.6M |
| 毛利率 | 63.1% | 70.9% |
| 营业利润率 | 9.2% | 1.1% |
| 净利率 | 2.1% | 2.7% |
| 营收同比 | 19.2% | 27.1% |
| 净利润同比 | 114.7% | 518.5% |
| 每股收益（稀释后） | $0.06 | $0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTIRTC
| Q4 25 | $116.0M | $208.9M | ||
| Q3 25 | $113.4M | $192.9M | ||
| Q2 25 | $113.0M | $186.7M | ||
| Q1 25 | $99.0M | $158.7M | ||
| Q4 24 | $97.3M | $164.3M | ||
| Q3 24 | $95.8M | $147.5M | ||
| Q2 24 | $98.0M | $148.0M | ||
| Q1 24 | $97.4M | $131.9M |
净利润AORTIRTC
| Q4 25 | $2.4M | $5.6M | ||
| Q3 25 | $6.5M | $-5.2M | ||
| Q2 25 | $1.3M | $-14.2M | ||
| Q1 25 | $-505.0K | $-30.7M | ||
| Q4 24 | $-16.5M | $-1.3M | ||
| Q3 24 | $-2.3M | $-46.2M | ||
| Q2 24 | $-2.1M | $-20.1M | ||
| Q1 24 | $7.5M | $-45.7M |
毛利率AORTIRTC
| Q4 25 | 63.1% | 70.9% | ||
| Q3 25 | 65.6% | 71.1% | ||
| Q2 25 | 64.7% | 71.2% | ||
| Q1 25 | 64.2% | 68.8% | ||
| Q4 24 | 63.2% | 70.0% | ||
| Q3 24 | 63.7% | 68.8% | ||
| Q2 24 | 64.6% | 69.9% | ||
| Q1 24 | 64.6% | 66.3% |
营业利润率AORTIRTC
| Q4 25 | 9.2% | 1.1% | ||
| Q3 25 | 11.1% | -4.4% | ||
| Q2 25 | 7.4% | -10.0% | ||
| Q1 25 | 2.2% | -20.5% | ||
| Q4 24 | 2.7% | -2.5% | ||
| Q3 24 | 4.6% | -34.1% | ||
| Q2 24 | 6.6% | -15.5% | ||
| Q1 24 | 26.0% | -28.9% |
净利率AORTIRTC
| Q4 25 | 2.1% | 2.7% | ||
| Q3 25 | 5.7% | -2.7% | ||
| Q2 25 | 1.2% | -7.6% | ||
| Q1 25 | -0.5% | -19.3% | ||
| Q4 24 | -16.9% | -0.8% | ||
| Q3 24 | -2.4% | -31.3% | ||
| Q2 24 | -2.2% | -13.6% | ||
| Q1 24 | 7.7% | -34.6% |
每股收益（稀释后）AORTIRTC
| Q4 25 | $0.06 | $0.18 | ||
| Q3 25 | $0.13 | $-0.16 | ||
| Q2 25 | $0.03 | $-0.44 | ||
| Q1 25 | $-0.01 | $-0.97 | ||
| Q4 24 | $-0.40 | $-0.03 | ||
| Q3 24 | $-0.05 | $-1.48 | ||
| Q2 24 | $-0.05 | $-0.65 | ||
| Q1 24 | $0.18 | $-1.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $583.8M |
| 总债务越低越好 | $215.1M | — |
| 股东权益账面价值 | $448.2M | $152.7M |
| 总资产 | $884.8M | $1.0B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AORTIRTC
| Q4 25 | $64.9M | $583.8M | ||
| Q3 25 | $73.4M | $565.2M | ||
| Q2 25 | $53.5M | $545.5M | ||
| Q1 25 | $37.7M | $520.6M | ||
| Q4 24 | $53.5M | $535.6M | ||
| Q3 24 | $56.2M | $522.0M | ||
| Q2 24 | $55.0M | $561.5M | ||
| Q1 24 | $51.1M | $569.1M |
总债务AORTIRTC
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTIRTC
| Q4 25 | $448.2M | $152.7M | ||
| Q3 25 | $438.7M | $121.9M | ||
| Q2 25 | $419.9M | $103.7M | ||
| Q1 25 | $294.3M | $86.7M | ||
| Q4 24 | $276.2M | $90.9M | ||
| Q3 24 | $304.7M | $71.8M | ||
| Q2 24 | $295.1M | $99.2M | ||
| Q1 24 | $295.0M | $90.3M |
总资产AORTIRTC
| Q4 25 | $884.8M | $1.0B | ||
| Q3 25 | $857.7M | $995.2M | ||
| Q2 25 | $838.4M | $964.0M | ||
| Q1 25 | $791.2M | $926.1M | ||
| Q4 24 | $789.1M | $931.4M | ||
| Q3 24 | $803.1M | $909.7M | ||
| Q2 24 | $789.5M | $919.2M | ||
| Q1 24 | $784.0M | $909.8M |
负债/权益比AORTIRTC
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $14.5M |
| 自由现金流率自由现金流/营收 | -6.9% | 6.9% |
| 资本支出强度资本支出/营收 | 23.7% | 5.6% |
| 现金转化率经营现金流/净利润 | 8.06× | 4.70× |
| 过去12个月自由现金流最近4个季度 | $839.0K | $34.5M |
8季度趋势，按日历期对齐
经营现金流AORTIRTC
| Q4 25 | $19.6M | $26.2M | ||
| Q3 25 | $22.3M | $34.9M | ||
| Q2 25 | $15.0M | $27.7M | ||
| Q1 25 | $-17.0M | $-7.9M | ||
| Q4 24 | $10.1M | $19.2M | ||
| Q3 24 | $11.5M | $24.3M | ||
| Q2 24 | $6.1M | $11.8M | ||
| Q1 24 | $-5.5M | $-52.0M |
自由现金流AORTIRTC
| Q4 25 | $-7.9M | $14.5M | ||
| Q3 25 | $17.7M | $20.1M | ||
| Q2 25 | $11.7M | $17.3M | ||
| Q1 25 | $-20.6M | $-17.3M | ||
| Q4 24 | $8.7M | $12.4M | ||
| Q3 24 | $7.8M | $15.5M | ||
| Q2 24 | $3.6M | $3.4M | ||
| Q1 24 | $-9.1M | $-61.8M |
自由现金流率AORTIRTC
| Q4 25 | -6.9% | 6.9% | ||
| Q3 25 | 15.6% | 10.4% | ||
| Q2 25 | 10.4% | 9.3% | ||
| Q1 25 | -20.8% | -10.9% | ||
| Q4 24 | 9.0% | 7.5% | ||
| Q3 24 | 8.2% | 10.5% | ||
| Q2 24 | 3.7% | 2.3% | ||
| Q1 24 | -9.3% | -46.8% |
资本支出强度AORTIRTC
| Q4 25 | 23.7% | 5.6% | ||
| Q3 25 | 4.1% | 7.7% | ||
| Q2 25 | 2.9% | 5.6% | ||
| Q1 25 | 3.7% | 5.9% | ||
| Q4 24 | 1.5% | 4.2% | ||
| Q3 24 | 3.8% | 6.0% | ||
| Q2 24 | 2.6% | 5.7% | ||
| Q1 24 | 3.7% | 7.4% |
现金转化率AORTIRTC
| Q4 25 | 8.06× | 4.70× | ||
| Q3 25 | 3.42× | — | ||
| Q2 25 | 11.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.73× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
